Ahren Will Launch its Webinar Series “A Glimpse into the Future” on The Cutting Edge Stage at CognitionX

23 June, 2020

(Above) Five of ten Ahren Founding & Science Partners in action on stage. From left to right: Professor John Daugman OBE, Professor Andy Parker, Professor Steve Jackson, Sir Shankar Balasubramanian and Alice Newcombe Ellis.

Ahren is delighted to announce its “A Glimpse into the Future” webinar series! The series will launch on The Cutting Edge stage at the CogX Global Leadership Summit and Festival of AI & Breakthrough Technology, the largest event of its kind, on Wednesday 10th June at 10:00 a.m. (BST)!

You can sign up here to stay up to date with our webinar series

The series will kick off with “A Glimpse into the Future with Science Partners from Ahren” with speakers including:

 

  • Alice Newcombe-Ellis – Founding and Managing Partner of Ahren Innovation Capital, an institution that invests at the intersection of deep technology and deep science.
  • Sir Shankar Balasubramanian – Ahren Science Partner, Principal Inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN.
  • Professor Steve Jackson – Ahren Science Partner, Originator of Olaparib/Lynparza, recently partnered by AstraZeneca with Merck and valued as an asset at up to $17BN and used to treat 30,000 patients worldwide to date.
  • The series will continue, giving you opportunity to engage with each Ahren Science Partner as they apply their expertise and unique insight to the areas of change and development that have the opportunity to create the companies of tomorrow.

Follow us on Twitter at @AhrenLP and LinkedIn to stay up to date with Ahren’s latest thinking. Watch this space!

About Ahren Innovation Capital:

Ahren Innovation Capital is an investment institution that supports transformational companies at the intersection of deep tech and deep science that will penetrate, or create, massive markets. Ahren is a unique partnership of investment talent and best-in-class commercial scientists whose technologies are today valued in excess of $100BN combined.

Ahren believes in taking asymmetric, considered, risk that will deliver superior rewards – capturing a generational opportunity to provide smart capital to deep technology.

With a philosophy espousing the importance of relationships and trust, Ahren provides both patient and active capital to exceptional founders and teams, empowering them to succeed.

Ahren’s Founding and Science Partners include:

Alice Newcombe-Ellis, Founder & CEO, formerly an investor at TPG Capital and Lansdowne Partners, Double First Class degree in Mathematics and Master’s in Maths & Physics from the University of Cambridge; Fulbright and Baker Scholar at Harvard Business School.

Sir Shankar Balasubramanian, principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated worth >$30BN.

Professor Roberto Cipolla, Professor of Information Engineering at Cambridge University, Director of Toshiba Research Europe.

Professor John Daugman, Head of Artificial Intelligence Group of Cambridge University, inventor of IRIS (eye) recognition technology used to register 1.5BN citizens worldwide.

Professor Zoubin Ghahramani, world leader in machine learning, co-founder of Geometric Intelligence, sold to Uber for an undisclosed amount.

Professor Steve Jackson, founder/co-founder of three companies and originator of Olaparib/Lynparza, recently partnered by AstraZeneca with Merck and valued as an asset at up to $17BN.

Professor Andy Parker, CERN leader, Head of the Cavendish Laboratory (Physics Department) of Cambridge University.

Sir Venki Ramakrishnan, Nobel prize laureate and President of the Royal Society, the UK’s premier science body.

Lord Martin Rees, world-renowned astrophysicist, Astronomer Royal, founder of CSER, former President of the Royal Society and former Master of Trinity College, Cambridge University.

Sir Gregory Winter, 2018 Nobel laureate, inventor of technology leading to Humira ($18BN sales in 2017, the world’s greatest grossing drug) and founder of three companies. Master of Trinity College, Cambridge University.

Disclaimer

The information provided by Ahren Innovation Capital LLP and its affiliates (“Ahren”, “we,” “us” or “our”) on https://www.ahreninnovationcapital.co.uk (the “Site”) is for general informational purposes only. Ahren is regulated by the Financial Conduct Authority. The investment products and services of Ahren are only available to professional clients and eligible counterparties as defined under FCA rules. They are not available to retail clients.

All information on the Site is provided in good faith, however, we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site. UNDER NO CIRCUMSTANCE SHALL WE HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE SITE OR RELIANCE ON ANY INFORMATION PROVIDED ON THE SITE. YOUR USE OF THE SITE AND YOUR RELIANCE ON ANY INFORMATION ON THE SITE IS SOLELY AT YOUR OWN RISK.

The Site may contain (or you may be sent through the Site) links to other websites or content belonging to or originating from third parties or links to websites and features in banners or other marketing. Such external links are not investigated, monitored, or checked for accuracy, adequacy, validity, reliability, availability or completeness by us. WE DO NOT WARRANT, ENDORSE, GUARANTEE, OR ASSUME RESPONSIBILITY FOR THE ACCURACY OR RELIABILITY OF ANY INFORMATION OFFERED BY THIRD¬PARTY WEBSITES LINKED THROUGH THE SITE OR ANY WEBSITE OR FEATURE LINKED IN ANY BANNER OR OTHER MARKETING. WE WILL NOT BE A PARTY TO OR IN ANY WAY BE RESPONSIBLE FOR MONITORING ANY TRANSACTION BETWEEN YOU AND THIRD¬PARTY PROVIDERS OF PRODUCTS OR SERVICES.

This event does not constitute an offer to buy or sell or a solicitation of an offer to buy securities in any company. This webinar is not intended for distribution to any other country where such distribution or use would be contrary to local law or regulation.

Investing in financial markets involves a substantial degree of risk. Nothing described herein is intended to imply that an investment is “safe”, “conservative”, “risk free” or “risk averse”. This event does not consider the specific investment objective, financial situation or particular needs of any client. The investment services of Ahren are intended only for investors who are capable of understanding the risk of loss of all or a substantial part of their monies. Investors in the UK are reminded that they will not benefit from the UK investors compensation scheme.

Nothing contained herein constitutes investment, legal, tax or other advice nor is to be relied upon in making an investment or other decision. No recommendation is made positive or otherwise, regarding individual securities or investments mentioned herein.

This event contains the opinions of the author and such opinions are subject to change without notice. The source of data is Ahren’s unless otherwise stated. No guarantee is made to the accuracy of the information provided which has been obtained from sources believed to be reliable.

No part of this the materials presented at this event may be divulged to any other person, distributed, resold and/or reproduced without the prior written permission of Ahren.

THE USE OR RELIANCE OF ANY INFORMATION CONTAINED ON THIS SITE IS SOLELY AT YOUR OWN RISK.

Please view Ahren’s Privacy Notice, here.

prev page About next page Covid-19 Update (Part 3 of 3): What Have we Learnt in the Last Six Weeks?

We use cookies to give you the best experience on our website. Learn more.

accept